<SEC-DOCUMENT>0001213900-25-085149.txt : 20250905
<SEC-HEADER>0001213900-25-085149.hdr.sgml : 20250905
<ACCEPTANCE-DATETIME>20250905172033
ACCESSION NUMBER:		0001213900-25-085149
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250905
DATE AS OF CHANGE:		20250905

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-79364
		FILM NUMBER:		251297530

	BUSINESS ADDRESS:	
		STREET 1:		501 E LAS OLAS BLVD
		STREET 2:		SUITE 300
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		501 E LAS OLAS BLVD
		STREET 2:		SUITE 300
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PMGC CAPITAL LLC
		CENTRAL INDEX KEY:			0002068010
		ORGANIZATION NAME:           	
		EIN:				331978501
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DRIVE
		STREET 2:		STE. 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		888-445-4886

	MAIL ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DRIVE
		STREET 2:		STE. 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: PMGC CAPITAL LLC -->
          <cik>0002068010</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <dateOfEvent>08/22/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001107421</issuerCIK>
        <issuerCUSIP>98973P309</issuerCUSIP>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <address>
          <com:street1>501 E LAS OLAS BLVD</com:street1>
          <com:street2>SUITE 300</com:street2>
          <com:city>FORT LAUDERDALE</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33301</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Ross D. Carmel, Esq.</personName>
          <personPhoneNum>2126580458</personPhoneNum>
          <personAddress>
            <com:street1>Sichenzia Ross Ference Carmel LLP</com:street1>
            <com:street2>1185 Avenue of the Americas, 31st Floor</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10036</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002068010</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>PMGC CAPITAL LLC</reportingPersonName>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>NV</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>0.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001840563</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>PMGC Holdings Inc.</reportingPersonName>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>NV</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>0.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>PMGC Holdings Inc. ("PMGC Holdings") is, as of the date of this Amendment No. 1, the sole member of PMGC Capital LLC ("PMGC LLC"). As of August 25, 2025 (please refer to Item 4 of this Amendment No. 1, below, for additional detail in relation to this date), the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock of the Issuer.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock</securityTitle>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>501 E LAS OLAS BLVD</com:street1>
          <com:street2>SUITE 300</com:street2>
          <com:city>FORT LAUDERDALE</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33301</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>Explanatory Note

Pursuant to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends and supplements the Schedule 13D originally filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2025 (the "Original Schedule 13D").

This Amendment No. 1 ("Amendment No. 1") relates to the common stock, par value $0.001 per share ("Common Stock"), of Alaunos Therapeutics, Inc., a Delaware corporation (the "Issuer"), owned by PMGC Capital LLC and PMGC Holdings Inc. (PMGC Capital LLC and PMGC Holdings Inc., collectively, the "Reporting Persons") and is the final amendment to the Original Schedule 13D and an exit filing for the Reporting Persons.</commentText>
      </item1>
      <item2>
        <filingPersonName>This Amendment No. 1 to Schedule 13D is filed on behalf of PMGC Capital LLC ("PMGC LLC"). PMGC Holdings Inc. ("PMGC Holdings") is currently the sole member of PMGC LLC. Currently, PMGC Holdings no longer exercises any voting and dispositive control over the Common Stock previously beneficially owned by PMGC LLC.</filingPersonName>
        <principalBusinessAddress>The principal business address of PMGC LLC is 120 Newport Center Drive, Ste. 249, Newport Beach, California 92660.</principalBusinessAddress>
        <principalJob>PMGC LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. PMGC LLC is a wholly-owned subsidiary of PMGC Holdings.</principalJob>
        <hasBeenConvicted>During the last five years, neither PMGC LLC nor PMGC Holdings has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).</hasBeenConvicted>
        <convictionDescription>During the last five years, neither PMGC LLC nor PMGC Holdings has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</convictionDescription>
        <citizenship>PMGC LLC is organized under the laws of Nevada.</citizenship>
      </item2>
      <item3>
        <fundsSource>Item 3 is hereby replaced in its entirety as follows:

Not applicable. This Amendment No. 1 reports the Transactions (as defined below).</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>Item 4 is hereby replaced in its entirety as follows:

Between June 16, 2025 and August 22, 2025, PMGC LLC sold all of Common Stock of the Issuer on the open market at prices ranging between $1.92 to $4.53 (such sales, in the aggregate, the "Transactions"). As of August 25, 2025, PMGC LLC's settlement date of the August 22, 2025 sales of the Issuer's Common Stock, the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Item 5(a) of the Original Schedule 13D is hereby replaced in its entirety as follows:

As of August 25, 2025, the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock.</percentageOfClassSecurities>
        <numberOfShares>Item 5(b) of the Original Schedule 13D is hereby replaced in its entirety as follows:

As of August 25, 2025, the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock.</numberOfShares>
        <transactionDesc>Item 5(c) of the Original Schedule 13D is hereby replaced in its entirety as follows:

Between June 16, 2025 and August 22, 2025, PMGC LLC sold all of the Common Stock of the Issuer on the open market at prices ranging between $1.92 to $4.53.</transactionDesc>
        <listOfShareholders>Not applicable.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>PMGC CAPITAL LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Graydon Bensler</signature>
          <title>Graydon Bensler, Manager of PMGC Capital LLC</title>
          <date>09/05/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>PMGC Holdings Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Graydon Bensler</signature>
          <title>Graydon Bensler, Chief Executive Officer of PMGC Holdings Inc.</title>
          <date>09/05/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
